vs
Side-by-side financial comparison of READING INTERNATIONAL INC (RDI) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
RHYTHM PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($57.3M vs $50.3M, roughly 1.1× READING INTERNATIONAL INC). READING INTERNATIONAL INC runs the higher net margin — -5.1% vs -83.0%, a 77.9% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs -14.2%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs 5.6%).
The Reading Company was a Philadelphia-headquartered railroad that provided passenger and freight transport in eastern Pennsylvania and neighboring states from 1924 until its acquisition by Conrail in 1976.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
RDI vs RYTM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $50.3M | $57.3M |
| Net Profit | $-2.6M | $-47.5M |
| Gross Margin | — | 91.6% |
| Operating Margin | -1.9% | -82.2% |
| Net Margin | -5.1% | -83.0% |
| Revenue YoY | -14.2% | 36.9% |
| Net Profit YoY | -14.5% | -9.6% |
| EPS (diluted) | $-0.11 | $-0.73 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $50.3M | $57.3M | ||
| Q3 25 | $52.2M | $51.3M | ||
| Q2 25 | $60.4M | $48.5M | ||
| Q1 25 | $40.2M | $32.7M | ||
| Q4 24 | $58.6M | $41.8M | ||
| Q3 24 | $60.1M | $33.3M | ||
| Q2 24 | $46.8M | $29.1M | ||
| Q1 24 | $45.1M | $26.0M |
| Q4 25 | $-2.6M | $-47.5M | ||
| Q3 25 | $-4.2M | $-52.9M | ||
| Q2 25 | $-2.7M | $-46.6M | ||
| Q1 25 | $-4.8M | $-49.5M | ||
| Q4 24 | $-2.2M | $-43.3M | ||
| Q3 24 | $-7.0M | $-43.6M | ||
| Q2 24 | $-12.8M | $-32.3M | ||
| Q1 24 | $-13.2M | $-141.4M |
| Q4 25 | — | 91.6% | ||
| Q3 25 | — | 89.3% | ||
| Q2 25 | — | 88.6% | ||
| Q1 25 | — | 88.8% | ||
| Q4 24 | — | 90.9% | ||
| Q3 24 | — | 88.5% | ||
| Q2 24 | — | 89.9% | ||
| Q1 24 | — | 89.2% |
| Q4 25 | -1.9% | -82.2% | ||
| Q3 25 | -0.6% | -102.6% | ||
| Q2 25 | 4.8% | -93.4% | ||
| Q1 25 | -17.2% | -143.7% | ||
| Q4 24 | 2.6% | -98.6% | ||
| Q3 24 | -0.6% | -132.0% | ||
| Q2 24 | -16.4% | -139.2% | ||
| Q1 24 | -16.7% | -538.7% |
| Q4 25 | -5.1% | -83.0% | ||
| Q3 25 | -8.0% | -103.1% | ||
| Q2 25 | -4.4% | -96.1% | ||
| Q1 25 | -11.8% | -151.4% | ||
| Q4 24 | -3.8% | -103.6% | ||
| Q3 24 | -11.7% | -131.2% | ||
| Q2 24 | -27.4% | -110.9% | ||
| Q1 24 | -29.4% | -544.4% |
| Q4 25 | $-0.11 | $-0.73 | ||
| Q3 25 | $-0.18 | $-0.82 | ||
| Q2 25 | $-0.12 | $-0.75 | ||
| Q1 25 | $-0.21 | $-0.81 | ||
| Q4 24 | $-0.11 | $-0.71 | ||
| Q3 24 | $-0.31 | $-0.73 | ||
| Q2 24 | $-0.57 | $-0.55 | ||
| Q1 24 | $-0.59 | $-2.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $10.5M | $388.9M |
| Total DebtLower is stronger | $185.1M | — |
| Stockholders' EquityBook value | $-18.2M | $139.1M |
| Total Assets | $434.9M | $480.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $10.5M | $388.9M | ||
| Q3 25 | $8.1M | $416.1M | ||
| Q2 25 | $9.1M | $291.0M | ||
| Q1 25 | $5.9M | $314.5M | ||
| Q4 24 | $12.4M | $320.6M | ||
| Q3 24 | $10.1M | $298.4M | ||
| Q2 24 | $9.3M | $319.1M | ||
| Q1 24 | $7.5M | $201.2M |
| Q4 25 | $185.1M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $202.7M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-18.2M | $139.1M | ||
| Q3 25 | $-12.1M | $148.8M | ||
| Q2 25 | $-7.7M | $-11.9M | ||
| Q1 25 | $-8.1M | $18.9M | ||
| Q4 24 | $-4.4M | $21.7M | ||
| Q3 24 | $1.6M | $11.2M | ||
| Q2 24 | $6.5M | $39.3M | ||
| Q1 24 | $18.0M | $61.6M |
| Q4 25 | $434.9M | $480.2M | ||
| Q3 25 | $435.2M | $506.9M | ||
| Q2 25 | $438.1M | $372.7M | ||
| Q1 25 | $441.0M | $386.7M | ||
| Q4 24 | $471.0M | $392.3M | ||
| Q3 24 | $495.7M | $363.6M | ||
| Q2 24 | $494.9M | $381.8M | ||
| Q1 24 | $494.9M | $258.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $4.3M | $-25.4M |
| Free Cash FlowOCF − Capex | $4.1M | — |
| FCF MarginFCF / Revenue | 8.2% | — |
| Capex IntensityCapex / Revenue | 0.3% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-2.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $4.3M | $-25.4M | ||
| Q3 25 | $295.0K | $-26.6M | ||
| Q2 25 | $1.6M | $-23.3M | ||
| Q1 25 | $-7.7M | $-40.4M | ||
| Q4 24 | $8.0M | $-18.8M | ||
| Q3 24 | $1.3M | $-25.2M | ||
| Q2 24 | $-10.4M | $-29.1M | ||
| Q1 24 | $-2.8M | $-40.7M |
| Q4 25 | $4.1M | — | ||
| Q3 25 | $-246.0K | — | ||
| Q2 25 | $1.2M | — | ||
| Q1 25 | $-8.0M | — | ||
| Q4 24 | $7.0M | — | ||
| Q3 24 | $-1.1M | — | ||
| Q2 24 | $-10.6M | — | ||
| Q1 24 | $-4.7M | — |
| Q4 25 | 8.2% | — | ||
| Q3 25 | -0.5% | — | ||
| Q2 25 | 1.9% | — | ||
| Q1 25 | -19.8% | — | ||
| Q4 24 | 12.0% | — | ||
| Q3 24 | -1.8% | — | ||
| Q2 24 | -22.7% | — | ||
| Q1 24 | -10.4% | — |
| Q4 25 | 0.3% | — | ||
| Q3 25 | 1.0% | — | ||
| Q2 25 | 0.6% | — | ||
| Q1 25 | 0.6% | — | ||
| Q4 24 | 1.7% | — | ||
| Q3 24 | 4.0% | — | ||
| Q2 24 | 0.5% | — | ||
| Q1 24 | 4.3% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RDI
| Cinema Exhibition Segment | $46.9M | 93% |
| Real Estate Revenue | $3.4M | 7% |
RYTM
Segment breakdown not available.
